PDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019

May 2, 2019 |

1 min read

PDL BioPharma, Inc. announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after market close.

INCLINE VILLAGE, Nev., May 2, 2019 /PRNewswire/ -- PDL BioPharma, Inc. (“PDL” or “the Company”) (NASDAQ: PDLI) today announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after market close. PDL’s management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com.

Conference Call Details
To access the live conference call via phone, please dial (844) 535-4071 from the United States and Canada or (706) 679-2458 internationally. The conference ID is 1099595. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1099595.

To access the live and subsequently archived webcast of the conference call, go to the Company’s website and go to “Events & Presentations.” Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
PDL BioPharma seeks to provide a significant return for its stockholders by entering into actively managed, strategic transactions involving late clinical- or early commercial-stage pharmaceutical companies or products with multiple year revenue growth potential. For more information please visit www.pdl.com.

NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)